Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Author(s): Ruixiang Guo, Huiru Dai, Fuweijian Liu, Minling Liu, Xueying Li, Tingwei Li, Jiehao Liao, Zhe-Sheng Chen*, Yuchen Liu* and Shuo Fang*

DOI: 10.2174/1574892817666220831122226

DownloadDownload PDF Flyer Cite As
The Prognostic and Drug-targeting Value of Lymphoid Enhancer-binding Factor-1 in Hepatocellular Carcinoma

Page: [211 - 223] Pages: 13

  • * (Excluding Mailing and Handling)

Abstract

Background: Lymphoid Enhancer-Binding Factor-1 (LEF1) was previously reported to contribute to a variety of malignancies, including Hepatocellular Carcinoma (HCC). However, its role in HCC is poorly understood.

Objectives: To explore the role of LEF1 in HCC, including its prognostic and drug-targeting value.

Methods: The LEF1 expression and patient characteristics were investigated. The associations between clinical characteristics and LEF1 were analyzed using both univariate and multivariate logistic regression. Cox regression and Kaplan-Meier curves were used to explore the clinicopathological factors related to overall survival in patients with HCC. A nomogram to predict the survival rate was constructed and validated. The Kyoto Encyclopedia of Genes and Genomes database (KEGG) was used to explore the function of LEF1. Gene Set Enrichment Analysis (GSEA) was also performed using The Cancer Genome Atlas dataset. Furthermore, compounds that may have the potential to be targeted drugs in the treatment of LEF1-overexpressing HCC were identified using the Comparative Toxicogenomics Database (CTD), patents about these drugs in HCC were also reviewed through Worldwide Espacenet® and Patentscope®.

Results: Increased expression of LEF1 was significantly associated with high histological grade of HCC (odds ratio (OR) = 2.521 for grade (G) 2 vs. G1, OR = 2.550 for G3 vs. G1, OR = 7.081 for G4 vs. G1, all P < 0.05). A Kaplan–Meier survival curve showed that HCC patients with LEF1 overexpression had a poor prognosis compared with those with normal LEF1 expression (P = 0.025). Multivariate Cox regression analysis revealed that LEF1 is an independent prognostic factor for the overall survival of patients with HCC (Hazard Ratio (HR) = 1.095; P = 0.04). The constructed nomogram to predict the survival rate produced a statistically significant prediction (area under the curve (AUC) = 86.68). In addition, Gene Ontology (GO) and KEGG analysis of genes co-expressed with the protein showed that LEF1 was associated with transcriptional regulation. GSEA suggested that the cell cycle, the WNT signaling pathway, and the NOTCH signaling pathway may be the key pathways regulated by LEF1 in HCC. Furthermore, the Comparative Toxicogenomics Database (CTD) identified nine compounds that may have the potential to be targeted drugs in the treatment of LEF1-overexpressing HCC. Patent reviews suggested that these drugs may show some efficacy in HCC, but whether these drugs interact with LEF1 and improve the prognosis for patients with HCC remains to be explored.

Conclusion: LEF1 is a latent prognostic molecular biomarker of HCC. The cell cycle, and WNT and NOTCH signaling pathways are regulated by LEF1 in HCC. LEF1 could be a potential drug target for HCC.

Keywords: Hepatocellular carcinoma, LEF1, oncogene, NOTCH, WNT, prognostic biomarker, drug target.

[1]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
Fernández-Palanca P, Fondevila F, Méndez-Blanco C, Tuñón MJ, González-Gallego J, Mauriz JL. Antitumor effects of quercetin in hepatocarcinoma in vitro and in vivo models: A systematic review. Nutrients 2019; 11(12): 2875.
[http://dx.doi.org/10.3390/nu11122875] [PMID: 31775362]
[3]
Colombo M, Maisonneuve P. Controlling liver cancer mortality on a global scale: Still a long way to go. J Hepatol 2017; 67(2): 216-7.
[http://dx.doi.org/10.1016/j.jhep.2017.05.004] [PMID: 28506906]
[4]
Kim DW, Talati C, Kim R. Hepatocellular carcinoma (HCC): Beyond sorafenib-chemotherapy. J Gastrointest Oncol 2017; 8(2): 256-65.
[http://dx.doi.org/10.21037/jgo.2016.09.07] [PMID: 28480065]
[5]
Cabral LKD, Tiribelli C, Sukowati CHC. Sorafenib resistance in hepatocellular carcinoma: The relevance of genetic heterogeneity. Cancers (Basel) 2020; 12(6): E1576.
[http://dx.doi.org/10.3390/cancers12061576] [PMID: 32549224]
[6]
Hsu CC, Hsieh PM, Chen YS, et al. Axl and autophagy LC3 expression in tumors is strongly associated with clinical prognosis of hepatocellular carcinoma patients after curative resection. Cancer Med 2019; 8(7): 3453-63.
[http://dx.doi.org/10.1002/cam4.2229] [PMID: 31094090]
[7]
Li L, Wang H. Heterogeneity of liver cancer and personalized therapy. Cancer Lett 2016; 379(2): 191-7.
[http://dx.doi.org/10.1016/j.canlet.2015.07.018] [PMID: 26213370]
[8]
Fu J, Wang H. Precision diagnosis and treatment of liver cancer in China. Cancer Lett 2018; 412: 283-8.
[http://dx.doi.org/10.1016/j.canlet.2017.10.008] [PMID: 29050983]
[9]
Ikeda K, Kudo M, Kawazoe S, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 2017; 52(4): 512-9.
[http://dx.doi.org/10.1007/s00535-016-1263-4] [PMID: 27704266]
[10]
Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381(9863): 295-302.
[http://dx.doi.org/10.1016/S0140-6736(12)61857-1] [PMID: 23177515]
[11]
Lu X, Paliogiannis P, Calvisi DF, Chen X. Role of the mammalian target of rapamycin pathway in liver cancer: From molecular genetics to targeted therapies. Hepatology 2021; 73 (Suppl. 1): 49-61.
[12]
Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther 2020; 5(1): 146.
[http://dx.doi.org/10.1038/s41392-020-00264-x] [PMID: 32782275]
[13]
Zhao Y, Zhang YN, Wang KT, Chen L. Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy. Biochim Biophys Acta Rev Cancer 2020; 1874(1): 188391.
[http://dx.doi.org/10.1016/j.bbcan.2020.188391] [PMID: 32659252]
[14]
Bai DS, Zhang C, Chen P, Jin SJ, Jiang GQ. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep 2017; 7(1): 12870.
[http://dx.doi.org/10.1038/s41598-017-12834-1] [PMID: 28993684]
[15]
Santiago L, Daniels G, Wang D, Deng FM, Lee P. Wnt signaling pathway protein LEF1 in cancer, as a biomarker for prognosis and a target for treatment. Am J Cancer Res 2017; 7(6): 1389-406.
[PMID: 28670499]
[16]
Bigas A, Guillén Y, Schoch L, Arambilet D. Revisiting β-catenin signaling in T-cell development and T-cell acute lymphoblastic leukemia. BioEssays 2020; 42(2): e1900099.
[http://dx.doi.org/10.1002/bies.201900099] [PMID: 31854474]
[17]
Zhao Y, Li C, Huang L, et al. Prognostic value of association of OCT4 with LEF1 expression in esophageal squamous cell carcinoma and their impact on epithelial-mesenchymal transition, invasion, and migration. Cancer Med 2018; 7(8): 3977-87.
[http://dx.doi.org/10.1002/cam4.1641] [PMID: 29974668]
[18]
Liang J, Li X, Li Y, et al. LEF1 targeting EMT in prostate cancer invasion is mediated by miR-181a. Am J Cancer Res 2015; 5(3): 1124-32.
[PMID: 26045991]
[19]
Fang S, Liu M, Li L, et al. Lymphoid enhancer-binding factor-1 promotes stemness and poor differentiation of hepatocellular carcinoma by directly activating the NOTCH pathway. Oncogene 2019; 38(21): 4061-74.
[http://dx.doi.org/10.1038/s41388-019-0704-y] [PMID: 30696957]
[20]
Yu G, Wang LG, Yan GR, He QY. DOSE: An R/Bioconductor package for disease ontology semantic and enrichment analysis. Bioinformatics 2015; 31(4): 608-9.
[http://dx.doi.org/10.1093/bioinformatics/btu684] [PMID: 25677125]
[21]
Lin S, Zhang W, Shi Z, et al. β-Catenin/LEF-1 transcription complex is responsible for the transcriptional activation of LINC01278. Cancer Cell Int 2021; 21(1): 380.
[http://dx.doi.org/10.1186/s12935-021-02082-9] [PMID: 34273985]
[22]
Hao YH, Lafita-Navarro MC, Zacharias L, et al. Induction of LEF1 by MYC activates the WNT pathway and maintains cell proliferation. Cell Commun Signal 2019; 17(1): 129.
[http://dx.doi.org/10.1186/s12964-019-0444-1] [PMID: 31623618]
[23]
Franceschini A, Szklarczyk D, Frankild S, et al. STRING v9.1: Protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 2013; 41(Database issue): D808-15.
[PMID: 23203871]
[24]
Zhong L, Yang S, Jia Y, Lei K. Inhibition of cyclin-dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis. J Cell Biochem 2018; 119(12): 9742-51.
[http://dx.doi.org/10.1002/jcb.27292] [PMID: 30145799]
[25]
Giovannini C, Bolondi L, Gramantieri L. Targeting Notch3 in hepatocellular carcinoma: Molecular mechanisms and therapeutic perspectives. Int J Mol Sci 2016; 18(1): 56.
[http://dx.doi.org/10.3390/ijms18010056] [PMID: 28036048]
[26]
Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 2013; 31(28): 3501-8.
[http://dx.doi.org/10.1200/JCO.2012.44.5643] [PMID: 23980077]
[27]
Amin A, Al Hrout Aa. Method of liver cancer treatment with safranal-based formulations patent. US Patent 20200253891A1, 2020.
[28]
Mylnikov AM, Navolokin NA, Mudrak DA. Method of combined liver cancer PC-1 therapy in experiment patent. RU Patent 0002734143, 2020.
[29]
Tang C, Joshi-Hangal R. Pharmaceutical formulation of decitabine patent. WO Patent 2006071491, 2006.
[30]
Tikhonov AV, Scherbakov VM, Volodarsky VI. Agent for treating primary liver cancer and a method of treating primary liver cancer patent. WO Patent 1996018410A1, 1996.
[31]
Van NA, Nghia ND, Hung KD, Binh NTN. Tricomponent solid lipid nano-composition comprising curcumin, ginger oleoresin, rutin having a cancer-cell killing property and method of preparing the same patent. WO Patent 2021232072A1, 2021.
[32]
Kinoshita Y, Sugimoto M, Ishiguro T. Therapeutic for hepatic cancer patent. WO Patent 2009122667A1, 2009.
[33]
Icard P, Simula L, Wu Z, et al. Why may citrate sodium significantly increase the effectiveness of transarterial chemoembolization in hepatocellular carcinoma? Drug Resist Updat 2021; 59: 100790.
[http://dx.doi.org/10.1016/j.drup.2021.100790] [PMID: 34924279]
[34]
Zirkel A, Lederer M, Stöhr N, Pazaitis N, Hüttelmaier S. IGF2BP1 promotes mesenchymal cell properties and migration of tumor-derived cells by enhancing the expression of LEF1 and SNAI2 (SLUG). Nucleic Acids Res 2013; 41(13): 6618-36.
[http://dx.doi.org/10.1093/nar/gkt410] [PMID: 23677615]
[35]
Kobayashi W, Ozawa M. The transcription factor LEF-1 induces an epithelial-mesenchymal transition in MDCK cells independent of β-catenin. Biochem Biophys Res Commun 2013; 442(1-2): 133-8.
[http://dx.doi.org/10.1016/j.bbrc.2013.11.031] [PMID: 24269234]
[36]
Mayer C-D, Giclais SM, Alsehly F, Hoppler S. Diverse LEF/TCF expression in human colorectal cancer correlates with altered Wnt-regulated transcriptome in a meta-analysis of patient biopsies. Genes (Basel) 2020; 11(5): 538.
[http://dx.doi.org/10.3390/genes11050538] [PMID: 32403323]
[37]
Gao X, Mi Y, Ma Y, Jin W. LEF1 regulates glioblastoma cell proliferation, migration, invasion, and cancer stem-like cell self-renewal. Tumour Biol 2014; 35(11): 11505-11.
[http://dx.doi.org/10.1007/s13277-014-2466-z] [PMID: 25128061]
[38]
Man Z, Pang Q, Zhou L, et al. Prognostic significance of preoperative prognostic nutritional index in hepatocellular carcinoma: A meta-analysis. HPB (Oxford) 2018; 20(10): 888-95.
[http://dx.doi.org/10.1016/j.hpb.2018.03.019] [PMID: 29853431]
[39]
Wu W, Zhu H, Fu Y, et al. High LEF1 expression predicts adverse prognosis in chronic lymphocytic leukemia and may be targeted by ethacrynic acid. Oncotarget 2016; 7(16): 21631-43.
[http://dx.doi.org/10.18632/oncotarget.7795] [PMID: 26950276]
[40]
Su MC, Chen CT, Huang FI, Chen YL, Jeng YM, Lin CY. Expression of LEF1 is an independent prognostic factor for patients with oral squamous cell carcinoma. J Formos Med Assoc 2014; 113(12): 934-9.
[http://dx.doi.org/10.1016/j.jfma.2013.07.012] [PMID: 24021930]
[41]
Wang WJ, Yao Y, Jiang LL, et al. Increased LEF1 expression and decreased Notch2 expression are strong predictors of poor outcomes in colorectal cancer patients. Dis Markers 2013; 35(5): 395-405.
[http://dx.doi.org/10.1155/2013/983981] [PMID: 24223455]
[42]
Jia M, Zhao HZ, Shen HP, et al. Overexpression of Lymphoid Enhancer-binding Factor-1 (LEF1) is a novel favorable prognostic factor in childhood acute lymphoblastic leukemia. Int J Lab Hematol 2015; 37(5): 631-40.
[http://dx.doi.org/10.1111/ijlh.12375] [PMID: 25955539]
[43]
Freihen V, Rönsch K, Mastroianni J, et al. SNAIL1 employs β-Catenin-LEF1 complexes to control colorectal cancer cell invasion and proliferation. Int J Cancer 2020; 146(8): 2229-42.
[http://dx.doi.org/10.1002/ijc.32644] [PMID: 31463973]
[44]
Bem J, Brożko N, Chakraborty C, et al. Wnt/β-catenin signaling in brain development and mental disorders: Keeping TCF7L2 in mind. FEBS Lett 2019; 593(13): 1654-74.
[http://dx.doi.org/10.1002/1873-3468.13502] [PMID: 31218672]
[45]
Duan J, He Y, Fu X, Deng Y, Zheng M, Lu D. CDK7 activated beta-catenin/TCF signaling in hepatocellular carcinoma. Exp Cell Res 2018; 370(2): 461-7.
[http://dx.doi.org/10.1016/j.yexcr.2018.07.010] [PMID: 29981747]
[46]
Wang Q, Li M, Zhang X, et al. Upregulation of CDK7 in gastric cancer cell promotes tumor cell proliferation and predicts poor prognosis. Exp Mol Pathol 2016; 100(3): 514-21.
[http://dx.doi.org/10.1016/j.yexmp.2016.05.001] [PMID: 27155449]
[47]
Li B, Ni Chonghaile T, Fan Y, et al. Therapeutic rationale to target highly expressed CDK7 conferring poor outcomes in triple-negative breast cancer. Cancer Res 2017; 77(14): 3834-45.
[http://dx.doi.org/10.1158/0008-5472.CAN-16-2546] [PMID: 28455421]
[48]
Patel H, Periyasamy M, Sava GP, et al. ICEC0942, an orally bioavailable selective inhibitor of CDK7 for cancer treatment. Mol Cancer Ther 2018; 17(6): 1156-66.
[http://dx.doi.org/10.1158/1535-7163.MCT-16-0847] [PMID: 29545334]
[49]
Wang J, Li Z, Mei H, et al. Antitumor effects of a covalent cyclin-dependent kinase 7 inhibitor in colorectal cancer. Anticancer Drugs 2019; 30(5): 466-74.
[http://dx.doi.org/10.1097/CAD.0000000000000749] [PMID: 30694816]
[50]
Wang WJ, Yao Y, Jiang LL, et al. Knockdown of lymphoid enhancer factor 1 inhibits colon cancer progression in vitro and in vivo. PLoS One 2013; 8(10): e76596.
[http://dx.doi.org/10.1371/journal.pone.0076596] [PMID: 24098538]
[51]
Shang D, Liu Y, Xu X, Han T, Tian Y. 5-aza-2′-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel by decreasing LEF1/phospho-β-catenin expression. Cancer Lett 2011; 311(2): 230-6.
[http://dx.doi.org/10.1016/j.canlet.2011.08.012] [PMID: 21880414]